128 related articles for article (PubMed ID: 7879419)
41. Protective immunity against Plasmodium yoelii malaria induced by immunization with particulate blood-stage antigens.
Burns JM; Dunn PD; Russo DM
Infect Immun; 1997 Aug; 65(8):3138-45. PubMed ID: 9234766
[TBL] [Abstract][Full Text] [Related]
42. Suppression of lethal Plasmodium yoelii malaria following protective immunization requires antibody-, IL-4-, and IFN-gamma-dependent responses induced by vaccination and/or challenge infection.
Petritus PM; Burns JM
J Immunol; 2008 Jan; 180(1):444-53. PubMed ID: 18097046
[TBL] [Abstract][Full Text] [Related]
43. Malaria DNA vaccines in Aotus monkeys.
Gramzinski RA; Maris DC; Doolan D; Charoenvit Y; Obaldia N; Rossan R; Sedegah M; Wang R; Hobart P; Margalith M; Hoffman S
Vaccine; 1997 Jun; 15(8):913-5. PubMed ID: 9234546
[TBL] [Abstract][Full Text] [Related]
44. Monoclonal antibodies of three different immunoglobulin G isotypes produced by immunization with a synthetic peptide or native protein protect mice against challenge with Plasmodium yoelii sporozoites.
Ak M; Bower JH; Hoffman SL; Sedegah M; Lees A; Carter M; Beaudoin RL; Charoenvit Y
Infect Immun; 1993 Jun; 61(6):2493-7. PubMed ID: 8500885
[TBL] [Abstract][Full Text] [Related]
45. Isolation and Characterization of Vaccine Candidate Genes Including
Kim SH; Bae YA; Seoh JY; Yang HJ
Korean J Parasitol; 2017 Jun; 55(3):255-265. PubMed ID: 28719950
[TBL] [Abstract][Full Text] [Related]
46. The complexity of protective immunity against liver-stage malaria.
Doolan DL; Hoffman SL
J Immunol; 2000 Aug; 165(3):1453-62. PubMed ID: 10903750
[TBL] [Abstract][Full Text] [Related]
47. Efficient induction of protective anti-malaria immunity by recombinant adenovirus.
Rodrigues EG; Zavala F; Nussenzweig RS; Wilson JM; Tsuji M
Vaccine; 1998 Nov; 16(19):1812-7. PubMed ID: 9795385
[TBL] [Abstract][Full Text] [Related]
48. Cytotoxic T cells recognize a peptide from the circumsporozoite protein on malaria-infected hepatocytes.
Weiss WR; Mellouk S; Houghten RA; Sedegah M; Kumar S; Good MF; Berzofsky JA; Miller LH; Hoffman SL
J Exp Med; 1990 Mar; 171(3):763-73. PubMed ID: 1689762
[TBL] [Abstract][Full Text] [Related]
49. Recombinant peptide replicates immunogenicity of synthetic linear peptide chimera for use as pre-erythrocytic stage malaria vaccine.
Silva-Flannery LM; Cabrera-Mora M; Jiang J; Moreno A
Microbes Infect; 2009 Jan; 11(1):83-91. PubMed ID: 19015042
[TBL] [Abstract][Full Text] [Related]
50. CD8+ cytolytic T cell clones derived against the Plasmodium yoelii circumsporozoite protein protect against malaria.
Rodrigues MM; Cordey AS; Arreaza G; Corradin G; Romero P; Maryanski JL; Nussenzweig RS; Zavala F
Int Immunol; 1991 Jun; 3(6):579-85. PubMed ID: 1716146
[TBL] [Abstract][Full Text] [Related]
51. Immunogenicity of Ty-VLP bearing a CD8(+) T cell epitope of the CS protein of P. yoelii: enhanced memory response by boosting with recombinant vaccinia virus.
Oliveira-Ferreira J; Miyahira Y; Layton GT; Savage N; Esteban M; Rodriguez D; Rodriguez JR; Nussenzweig RS; Zavala F
Vaccine; 2000 Mar; 18(17):1863-9. PubMed ID: 10699335
[TBL] [Abstract][Full Text] [Related]
52. Comparison of humoral immune responses elicited by DNA and protein vaccines based on merozoite surface protein-1 from Plasmodium yoelii, a rodent malaria parasite.
Kang Y; Calvo PA; Daly TM; Long CA
J Immunol; 1998 Oct; 161(8):4211-9. PubMed ID: 9780195
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of vaccines designed to induce protective cellular immunity against the Plasmodium yoelii circumsporozoite protein: vaccinia, pseudorabies, and Salmonella transformed with circumsporozoite gene.
Sedegah M; Beaudoin RL; Majarian WR; Cochran MD; Chiang CH; Sadoff J; Aggarwal A; Charoenvit Y; Hoffman SL
Bull World Health Organ; 1990; 68 Suppl(Suppl):109-14. PubMed ID: 2094576
[TBL] [Abstract][Full Text] [Related]
54. Active and passive immunization against Plasmodium yoelii sporozoites.
Charoenvit Y; Sedegah M; Yuan LF; Gross M; Cole C; Bechara R; Leef MF; Robey FA; Lowell GH; Beaudoin RL
Bull World Health Organ; 1990; 68 Suppl(Suppl):26-32. PubMed ID: 1709834
[TBL] [Abstract][Full Text] [Related]
55. Effects of transmission-blocking vaccines simultaneously targeting pre- and post-fertilization antigens in the rodent malaria parasite Plasmodium yoelii.
Zheng L; Pang W; Qi Z; Luo E; Cui L; Cao Y
Parasit Vectors; 2016 Aug; 9(1):433. PubMed ID: 27502144
[TBL] [Abstract][Full Text] [Related]
56. IL-12 and NK cells are required for antigen-specific adaptive immunity against malaria initiated by CD8+ T cells in the Plasmodium yoelii model.
Doolan DL; Hoffman SL
J Immunol; 1999 Jul; 163(2):884-92. PubMed ID: 10395683
[TBL] [Abstract][Full Text] [Related]
57. Nanoparticle formulation enhanced protective immunity provoked by PYGPI8p-transamidase related protein (PyTAM) DNA vaccine in Plasmodium yoelii malaria model.
Cherif MS; Shuaibu MN; Kodama Y; Kurosaki T; Helegbe GK; Kikuchi M; Ichinose A; Yanagi T; Sasaki H; Yui K; Tien NH; Karbwang J; Hirayama K
Vaccine; 2014 Apr; 32(17):1998-2006. PubMed ID: 24440206
[TBL] [Abstract][Full Text] [Related]
58. Protection of rhesus macaques against lethal Plasmodium knowlesi malaria by a heterologous DNA priming and poxvirus boosting immunization regimen.
Rogers WO; Weiss WR; Kumar A; Aguiar JC; Tine JA; Gwadz R; Harre JG; Gowda K; Rathore D; Kumar S; Hoffman SL
Infect Immun; 2002 Aug; 70(8):4329-35. PubMed ID: 12117942
[TBL] [Abstract][Full Text] [Related]
59. Escheriosome entrapped soluble blood stage antigens impart protective immunity against a multi-drug resistant isolate of Plasmodium yoelii nigeriensis in BALB/c mice.
Sharma SK; Farah D; Misra-Bhattacharya S; Bajpai P; Agarwal A; Mohammad O
Vaccine; 2006 Feb; 24(7):948-56. PubMed ID: 16168527
[TBL] [Abstract][Full Text] [Related]
60. Defining rules of CD8(+) T cell expansion against pre-erythrocytic Plasmodium antigens in sporozoite-immunized mice.
Billman ZP; Kas A; Stone BC; Murphy SC
Malar J; 2016 Apr; 15():238. PubMed ID: 27113469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
